Dr. Spiegel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
400 elm st
Westfield, NJ 07090
Education & Training
National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1977 - 1979
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1974 - 1977
Perelman School of Medicine at the University of PennsylvaniaClass of 1975
Yale UniversityB.A.
Certifications & Licensure
NY State Medical License 1976 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma.Brian A Van Tine, Matthew A Ingham, Steven Attia, Christian F Meyer, John D Baird
Journal of Clinical Oncology. 2024-07-10 - 5 citationsEmvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.Arthur Branstrom, Liangxian Cao, Bansri Furia, Christopher Trotta, Marianne Santaguida
Frontiers in Oncology. 2022-01-01 - 14 citationsPreclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent.Finith Jernigan, Arthur Branstrom, John D. Baird, Liangxian Cao, Mandar V. Dali
Molecular Cancer Therapeutics. 2021-07-26
Press Mentions
Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of DirectorsAugust 4th, 2020
What Will Happen to Cyclacel Pharmaceuticals, Inc. (CYCCP) Next? The Stock Formed a Several Months Descending Triangle PatternMarch 12th, 2019
Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy CompanyDecember 8th, 2018- Join now to see all
Professional Memberships
- Member
Industry Relationships
- Chief Medical Officer, Schering Plough1984 - 2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
